Shattuck Labs (STTK) Expected to Announce Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Stock Down 7.9%

Shares of NASDAQ:STTK opened at $0.77 on Thursday. The firm has a market cap of $36.84 million, a P/E ratio of -0.55 and a beta of 1.63. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $4.26. The company’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.04.

Institutional Trading of Shattuck Labs

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares during the period. Acadian Asset Management LLC grew its holdings in Shattuck Labs by 27.6% during the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after acquiring an additional 55,687 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Shattuck Labs during the 1st quarter valued at $81,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.